# Early Alzheimers Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/early-alzheimers-disease

> 2 upcoming FDA catalysts in early Alzheimers Disease: buntanetap/posiphen (ANVS) on December 2027 (primary completion); buntanetap/posiphen (ANVS) on Dec 2027 to Mar 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 2027 | [Buntanetap/posiphen primary completion](https://sec-api.dev/pdufa/buntanetap-posiphen) | ANVS | Early Alzheimers Disease | scheduled | "NCT06709014 (A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06709014)) |
| Dec 2027 to Mar 2028 | [Buntanetap/posiphen topline data readout](https://sec-api.dev/pdufa/buntanetap-posiphen) | ANVS | Early Alzheimers Disease | scheduled | "NCT06709014 (A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06709014)) |

## Drugs

- [Buntanetap/posiphen](https://sec-api.dev/pdufa/buntanetap-posiphen) (ANVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/early-alzheimers-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Early Alzheimers Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/early-alzheimers-disease

```bibtex
@misc{secapidev_indications_early_alzheimers_disease_20261116,
  title        = {Early Alzheimers Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/early-alzheimers-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_early_alzheimers_disease_20261116","title":"Early Alzheimers Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/early-alzheimers-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
